AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
teprenone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| mineralocorticoid receptor (MR, MCR, aldosterone receptor) antagonists | 2596 | 6809-52-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
; RN given refers to isomeric cpd without isomeric designation; mixture of (5E,9E,13E) & (5Z,9E,13E)-isomers
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK12,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PIM2,PLK1,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 58 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatic function abnormal | 86.08 | 25.35 | 38 | 2937 | 46250 | 90579222 |
| Interstitial lung disease | 76.31 | 25.35 | 41 | 2934 | 76364 | 90549108 |
| Platelet count decreased | 63.43 | 25.35 | 45 | 2930 | 136924 | 90488548 |
| Renal impairment | 51.95 | 25.35 | 36 | 2939 | 105385 | 90520087 |
| Anaemia | 49.02 | 25.35 | 59 | 2916 | 352743 | 90272729 |
| Upper respiratory tract inflammation | 47.14 | 25.35 | 12 | 2963 | 2660 | 90622812 |
| White blood cell count decreased | 45.16 | 25.35 | 40 | 2935 | 167069 | 90458403 |
| Cerebral haemorrhage | 38.61 | 25.35 | 20 | 2955 | 34502 | 90590970 |
| Aspartate aminotransferase increased | 32.59 | 25.35 | 27 | 2948 | 102910 | 90522562 |
| Gamma-glutamyltransferase increased | 31.36 | 25.35 | 18 | 2957 | 37934 | 90587538 |
| Alanine aminotransferase increased | 31.29 | 25.35 | 28 | 2947 | 118310 | 90507162 |
| Osteonecrosis of jaw | 30.86 | 25.35 | 18 | 2957 | 39085 | 90586387 |
| Cardiac failure | 29.13 | 25.35 | 26 | 2949 | 109470 | 90516002 |
| Pyrexia | 27.26 | 25.35 | 64 | 2911 | 660421 | 89965051 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Platelet count decreased | 51.23 | 23.27 | 51 | 2445 | 138530 | 42480309 |
| Hepatic function abnormal | 49.11 | 23.27 | 33 | 2463 | 51534 | 42567305 |
| Anaemia | 41.35 | 23.27 | 65 | 2431 | 280213 | 42338626 |
| Decreased appetite | 40.52 | 23.27 | 53 | 2443 | 193084 | 42425755 |
| Inappropriate antidiuretic hormone secretion | 29.89 | 23.27 | 16 | 2480 | 16525 | 42602314 |
| C-reactive protein increased | 28.36 | 23.27 | 26 | 2470 | 63534 | 42555305 |
| Liver disorder | 27.64 | 23.27 | 21 | 2475 | 39623 | 42579216 |
| White blood cell count decreased | 25.78 | 23.27 | 32 | 2464 | 110364 | 42508475 |
| Neutrophil count decreased | 24.58 | 23.27 | 24 | 2472 | 63391 | 42555448 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatic function abnormal | 126.50 | 20.95 | 71 | 5781 | 89224 | 110494223 |
| Platelet count decreased | 108.70 | 20.95 | 93 | 5759 | 230350 | 110353097 |
| Anaemia | 81.74 | 20.95 | 121 | 5731 | 546965 | 110036482 |
| Interstitial lung disease | 77.65 | 20.95 | 62 | 5790 | 139272 | 110444175 |
| White blood cell count decreased | 66.84 | 20.95 | 71 | 5781 | 229319 | 110354128 |
| Renal impairment | 59.67 | 20.95 | 61 | 5791 | 188384 | 110395063 |
| Upper respiratory tract inflammation | 56.31 | 20.95 | 17 | 5835 | 4354 | 110579093 |
| Hyperuricaemia | 45.97 | 20.95 | 20 | 5832 | 14511 | 110568936 |
| Neutrophil count decreased | 45.43 | 20.95 | 43 | 5809 | 120898 | 110462549 |
| Cerebral haemorrhage | 40.68 | 20.95 | 31 | 5821 | 64937 | 110518510 |
| Decreased appetite | 40.27 | 20.95 | 82 | 5770 | 475764 | 110107683 |
| Pyrexia | 38.18 | 20.95 | 119 | 5733 | 898146 | 109685301 |
| Inappropriate antidiuretic hormone secretion | 37.54 | 20.95 | 23 | 5829 | 33828 | 110549619 |
| Drug eruption | 36.70 | 20.95 | 27 | 5825 | 53632 | 110529815 |
| Disseminated intravascular coagulation | 35.74 | 20.95 | 24 | 5828 | 41262 | 110542185 |
| Enterocolitis | 35.01 | 20.95 | 18 | 5834 | 18931 | 110564516 |
| Liver disorder | 34.43 | 20.95 | 40 | 5812 | 142203 | 110441244 |
| Drug ineffective | 34.36 | 20.95 | 19 | 5833 | 1520521 | 109062926 |
| Gamma-glutamyltransferase increased | 33.50 | 20.95 | 27 | 5825 | 61282 | 110522165 |
| Cerebral infarction | 33.03 | 20.95 | 25 | 5827 | 51813 | 110531634 |
| Fatigue | 32.43 | 20.95 | 12 | 5840 | 1215946 | 109367501 |
| Erythema multiforme | 30.43 | 20.95 | 17 | 5835 | 21080 | 110562367 |
| Gastric ulcer haemorrhage | 29.04 | 20.95 | 13 | 5839 | 10081 | 110573366 |
| Alanine aminotransferase increased | 27.80 | 20.95 | 41 | 5811 | 183732 | 110399715 |
| Haemoglobin decreased | 27.37 | 20.95 | 48 | 5804 | 248679 | 110334768 |
| Osteonecrosis of jaw | 25.92 | 20.95 | 21 | 5831 | 47996 | 110535451 |
| Pneumonia | 25.82 | 20.95 | 103 | 5749 | 876611 | 109706836 |
| Malignant neoplasm progression | 25.05 | 20.95 | 38 | 5814 | 174529 | 110408918 |
| Gastric cancer | 24.90 | 20.95 | 12 | 5840 | 10996 | 110572451 |
| Aspartate aminotransferase increased | 24.65 | 20.95 | 36 | 5816 | 159900 | 110423547 |
| Cardiac failure | 24.36 | 20.95 | 39 | 5813 | 187587 | 110395860 |
| Colon cancer | 23.04 | 20.95 | 13 | 5839 | 16430 | 110567017 |
| C-reactive protein increased | 22.61 | 20.95 | 41 | 5811 | 217878 | 110365569 |
| Haemorrhage subcutaneous | 22.12 | 20.95 | 9 | 5843 | 5530 | 110577917 |
| Spinal compression fracture | 21.68 | 20.95 | 13 | 5839 | 18379 | 110565068 |
| Constipation | 21.64 | 20.95 | 54 | 5798 | 357732 | 110225715 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A02BX15 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) |
| MeSH PA | D000897 | Anti-Ulcer Agents |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D005765 | Gastrointestinal Agents |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:49201 | anti-ulcer drug |
| CHEBI has role | CHEBI:62868 | hepatoprotective agent |
| CHEBI has role | CHEBI:63726 | neuroprotective agent |
| CHEBI has role | CHEBI:76595 | nephroprotective agent |
| CHEBI has role | CHEBI:77307 | cardioprotective agent |
| CHEBI has role | CHEBI:78606 | Hsp70 inducer |
Related Drugs by ATC class:
A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) 15 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D01827 | KEGG_DRUG |
| 3796-63-2 | SECONDARY_CAS_RN |
| C0061231 | UMLSCUI |
| CHEBI:31649 | CHEBI |
| CHEMBL5314356 | ChEMBL_ID |
| DB15955 | DRUGBANK_ID |
| 5282199 | PUBCHEM_CID |
| C031049 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5412 | INN_ID |
| S8S8451A4O | UNII |
| 1362746 | RXNORM |
| S8S8451A4O | INXIGHT DRUGS |
Pharmaceutical products:
None